Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | EXEC. VP AND CLO | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,272 |
Ending reported balance
After 2026-10-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-09 · Exercise / conversion · Acquired 192 · Balance 105,464 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Row 2 · 2026-10-09 · Sale · Disposed 192 · Balance 105,272 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.42 · Expires 2033-01-04 | Direct | 2,267 |
Reported balance
After 2026-10-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-09 · Exercise / conversion · Disposed 192 · Balance 2,267 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5,662 | $53.02 | $300,199.24 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 9 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to $53.14 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 5,662 | $33.02 | $186,959.24 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 8 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,249 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · derivative · entry 14 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,751 Underlying: Common Stock · 11,249 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. F9 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,398 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · derivative · entry 13 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,114 Underlying: Common Stock · 11,398 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,392 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · derivative · entry 12 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,788 Underlying: Common Stock · 45,392 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,762 | $53.05 | $411,774.10 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 7 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.74 to $53.57 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,487 | $52.24 | $182,160.88 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,663 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.73 to $52.71 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 11,249 | $25.69 | $288,986.81 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 11,398 | $53.12 | $605,461.76 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to $53.57 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 11,398 | $33.02 | $376,361.96 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 45,392 | $53.15 | $2,412,584.80 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to $53.82 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 45,392 | $33.02 | $1,498,843.84 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,614 | $50.12 | $80,900.14 |
DisclosureSEC source: 0001415889-25-005134 · form4-02212025_050204.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a February 15, 2024 grant of 18,000 RSUs and the vesting of 1,600 RSUs from a February 15, 2024 grant of 3,200 RSUs. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,333 | $50.10 | $66,777.97 |
DisclosureSEC source: 0001415889-25-005134 · form4-02212025_050204.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,515 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a February 15, 2024 grant of 18,000 RSUs and the vesting of 1,600 RSUs from a February 15, 2024 grant of 3,200 RSUs. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,998 | $44.50 | $88,911.00 |
DisclosureSEC source: 0001415889-25-001291 · form4-01102025_050103.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,848 F2 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs and the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,543 | $45.34 | $69,959.62 |
DisclosureSEC source: 0001415889-25-001291 · form4-01102025_050103.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,846 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,250 RSUs from a January 5, 2023 grant of 17,000 RSUs. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001415889-25-001020 · form4-01072025_050111.xml · derivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2035-01-02 F2 · derivative.exercise_date: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001020 · form4-01072025_050111.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,389 F1 · shares: Restricted stock units granted on January 3, 2025 that vest in four equal installments over four years, commencing on January 3, 2026. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,988 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · derivative · entry 17 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,512 Underlying: Common Stock · 1,988 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,720 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · derivative · entry 16 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,110 Underlying: Common Stock · 7,720 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 600 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · derivative · entry 15 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,070 Underlying: Common Stock · 600 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 88 | $54.14 | $4,764.32 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 12 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,389 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,900 | $53.13 | $100,947.00 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 11 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,477 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to $53.62 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,988 | $33.02 | $65,643.76 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 10 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,405 | $54.05 | $75,940.25 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 9 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,389 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.025 to $54.16 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 6,315 | $53.14 | $335,579.10 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 8 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,794 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to 53.995 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 7,720 | $33.02 | $254,914.40 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 7 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 600 | $53.04 | $31,824.00 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,389 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to $53.09 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 600 | $33.02 | $19,812.00 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 83,640 | $0.00 Strike: $51.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · derivative · entry 14 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,640 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,960 | $0.00 Strike: $51.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · derivative · entry 13 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,640 Underlying: Common Stock · 1,960 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 83,640 | $52.26 | $4,371,026.40 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,389 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.00 to $52.91 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 83,640 | $51.00 | $4,265,640.00 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,960 | $52.17 | $102,253.20 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,389 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.00 to $52.83 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,960 | $51.00 | $99,960.00 |
DisclosureSEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-24-004104 · form4-02162024_040235.xml · derivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-02-14 F3 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004104 · form4-02162024_040235.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,389 F2 · shares: Restricted stock units granted on February 15, 2024 that vest in two equal installments over two years, commencing on February 15, 2025. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004104 · form4-02162024_040235.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,189 F1 · shares: Restricted stock units granted on February 15, 2024 that vest in four equal installments over four years, commencing on February 15, 2025. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 21:17 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 794 | $27.25 | $21,637.14 |
DisclosureSEC source: 0001415889-24-002173 · form4-02012024_090230.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,189 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 29, 2020 grant of 10,200 RSUs. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 21:04 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,938 | $29.01 | $56,230.68 |
DisclosureSEC source: 0001415889-24-000910 · form4-01102024_090136.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,983 F2 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs and the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:04 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,457 | $28.64 | $41,728.92 |
DisclosureSEC source: 0001415889-24-000910 · form4-01102024_090136.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,921 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,250 RSUs from a January 5, 2023 grant of 17,000 RSUs. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 58,631 | $30.86 Strike: $30.86 | $1,809,352.66 |
DisclosureSEC source: 0001415889-23-006694 · form4-04192023_080455.xml · derivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,631 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 2, 2022. F4 · derivative.exercise_date: Currently exercisable. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,292 | $30.86 Strike: $30.86 | $101,591.12 |
DisclosureSEC source: 0001415889-23-006694 · form4-04192023_080455.xml · derivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,631 Underlying: Common Stock · 3,292 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 2, 2022. F4 · derivative.exercise_date: Currently exercisable. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 58,631 | $51.42 | $3,014,553.91 |
DisclosureSEC source: 0001415889-23-006694 · form4-04192023_080455.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,378 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 2, 2022. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.00 to $51.825 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 58,631 | $30.86 | $1,809,352.66 |
DisclosureSEC source: 0001415889-23-006694 · form4-04192023_080455.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 2, 2022. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,292 | $51.42 | $169,276.29 |
DisclosureSEC source: 0001415889-23-006694 · form4-04192023_080455.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,378 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 2, 2022. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.00 to $51.79 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 3,292 | $30.86 | $101,591.12 |
DisclosureSEC source: 0001415889-23-006694 · form4-04192023_080455.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 2, 2022. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:18 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 812 | $45.63 | $37,049.94 |
DisclosureSEC source: 0001415889-23-001794 · form4-02022023_090220.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,378 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 29, 2020 grant of 10,200 RSUs. Read SEC document |
| January 11, 2023 Filed Jan 12, 2023 21:38 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 495 | $44.36 | $21,958.00 |
DisclosureSEC source: 0001415889-23-000882 · form4-01122023_090135.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,190 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:38 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 590 | $42.93 | $25,330.41 |
DisclosureSEC source: 0001415889-23-000882 · form4-01122023_090135.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,685 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.